Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:49:41+00:00May 8th, 2023|Read More
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:48:19+00:00May 8th, 2023|Read More
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:47:18+00:00May 8th, 2023|Read More
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressiveDanielle Drayton2023-05-08T11:43:35+00:00May 8th, 2023|Read More
Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:49:41+00:00May 8th, 2023|Read More
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:48:19+00:00May 8th, 2023|Read More
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:47:18+00:00May 8th, 2023|Read More
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressiveDanielle Drayton2023-05-08T11:43:35+00:00May 8th, 2023|Read More
